Stoke Therapeutics Sees Unusually High Options Volume (NASDAQ:STOK)

Stoke Therapeutics, Inc. (NASDAQ:STOK) saw unusually large options trading on Friday. Stock investors purchased 10,008 call options on the company. This represents an increase of 1,407% compared to the average daily volume of 664 call options.

Stoke Therapeutics Trading Up 5.0%

Shares of STOK stock opened at $29.34 on Friday. Stoke Therapeutics has a twelve month low of $5.35 and a twelve month high of $38.69. The stock has a fifty day simple moving average of $27.53 and a two-hundred day simple moving average of $18.35. The stock has a market capitalization of $1.68 billion, a price-to-earnings ratio of 43.79 and a beta of 1.32.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.11). The firm had revenue of $10.63 million for the quarter, compared to analysts’ expectations of $6.06 million. Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%. Research analysts predict that Stoke Therapeutics will post -2.01 EPS for the current fiscal year.

Insider Buying and Selling

In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 25,000 shares of Stoke Therapeutics stock in a transaction on Wednesday, October 8th. The shares were sold at an average price of $30.00, for a total transaction of $750,000.00. Following the completion of the transaction, the director directly owned 49,124 shares of the company’s stock, valued at $1,473,720. The trade was a 33.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Adrian R. Krainer sold 40,472 shares of the business’s stock in a transaction on Friday, November 14th. The shares were sold at an average price of $26.98, for a total transaction of $1,091,934.56. Following the transaction, the director owned 364,246 shares in the company, valued at $9,827,357.08. This trade represents a 10.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 213,367 shares of company stock valued at $5,110,464 in the last three months. Corporate insiders own 9.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in STOK. Corient Private Wealth LLC bought a new stake in shares of Stoke Therapeutics in the 2nd quarter valued at about $7,489,000. Wellington Management Group LLP increased its holdings in Stoke Therapeutics by 438.2% during the third quarter. Wellington Management Group LLP now owns 737,753 shares of the company’s stock valued at $17,337,000 after buying an additional 600,687 shares during the period. Polar Capital Holdings Plc raised its stake in Stoke Therapeutics by 49.8% in the third quarter. Polar Capital Holdings Plc now owns 1,323,470 shares of the company’s stock worth $31,102,000 after buying an additional 439,824 shares in the last quarter. Checkpoint Capital L.P. lifted its holdings in Stoke Therapeutics by 139.3% during the first quarter. Checkpoint Capital L.P. now owns 730,717 shares of the company’s stock worth $4,859,000 after buying an additional 425,330 shares during the period. Finally, Erste Asset Management GmbH bought a new stake in Stoke Therapeutics during the 1st quarter valued at $2,670,000.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on STOK. JPMorgan Chase & Co. raised their price objective on shares of Stoke Therapeutics from $15.00 to $25.00 and gave the stock a “neutral” rating in a research note on Monday, November 3rd. Chardan Capital upgraded Stoke Therapeutics to a “strong-buy” rating in a report on Wednesday. Needham & Company LLC boosted their price objective on Stoke Therapeutics from $22.00 to $35.00 and gave the company a “buy” rating in a report on Friday, October 10th. Canaccord Genuity Group upped their price objective on Stoke Therapeutics from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Finally, Wedbush lifted their target price on Stoke Therapeutics from $22.00 to $32.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 5th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $31.00.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.